New ASA Formulation for Secondary Prevention of CV Events

. . . but a different site of absorption–with greater predictability than ECASA. DON’T MISS IT!! @DLBHATTMD @cpcannon @AnnMarieNavar @DrM_ODonoghue @DrMarthaGulati @practicalcardio @GuyattGH @DrMauricioCohen @SVRaoMD @ASPCardio @PlateletDoc @stephanamayer...

Optimizing Duration of Antiplatelet Therapy After ACS/PCI

Watch here tomorrow a new accredited, serialized tweetorial on optimizing duration of antiplatelet therapy after ACS/PCI. Earn 0.5 CE/#CME credits: #physicians, #nurses, #pharmacists! Expert faculty @mirvatalasnag. #medtwitter @academiccme #cardiotwitter #FOAMed...

Antiplatelet Therapy in a STEMI Patient with Gastroparesis

Supported by educational grants from Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk. This program is intended for healthcare providers.— cardio-met (@cardiomet_CE) June 1, 2021 3) The patient states that his abd pain has worsened and spread to his chest. He is...